Tetracyclic
terpenoid-derived natural products are a broad class
of medically relevant agents that include well-known steroid hormones
and related structures, as well as more synthetically challenging
congeners such as limonoids, cardenolides, lanostanes, and cucurbitanes,
among others. These structurally related compound classes present
synthetically disparate challenges based, in part, on the position
and stereochemistry of the numerous quaternary carbon centers that
are common to their tetracyclic skeletons. While de novo syntheses
of such targets have been a topic of great interest for over 50 years,
semisynthesis is often how synthetic variants of these natural products
are explored as biologically relevant materials and how such agents
are further matured as therapeutics. Here, focus was directed at establishing
an efficient, stereoselective, and molecularly flexible de novo synthetic
approach that could offer what semisynthetic approaches do not. In
short, a unified strategy to access common molecular features of these
natural product families is described that proceeds in four stages:
(1) conversion of epichlorohydrin to stereodefined enynes, (2) metallacycle-mediated
annulative cross-coupling to generate highly substituted hydrindanes,
(3) tetracycle formation by stereoselective forging of the C9–C10
bond, and (4) group-selective oxidative rearrangement that repositions
a quaternary center from C9 to C10. These studies have defined the
structural features required for highly stereoselective C9–C10
bond formation and document the generality of this four-stage synthetic
strategy to access a range of unique stereodefined systems, many of
which bear stereochemistry/substitution/functionality not readily
accessible from semisynthesis.